The Food and Drug Administration on Monday approved a once-daily pill for sickle cell disease that works in an entirely new way — by boosting hemoglobin, the oxygen-carrying molecule found in red blood cells.

The novel drug was developed by the biotech firm Global Blood Therapeutics and will be sold under the brand name Oxbryta. The drug’s approval came three months earlier than expected.